These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Increase of energy transformation by hexoprenaline]. Irsigler K; Schlick W; Schütz P Arzneimittelforschung; 1971 Jan; 21(1):51-4. PubMed ID: 5108200 [No Abstract] [Full Text] [Related]
45. [The treatment of obesity in coronary disease patients]. Villela AA; Magalhães A; Leszek G Hospital (Rio J); 1966 Sep; 70(3):571-84. PubMed ID: 5300270 [No Abstract] [Full Text] [Related]
46. After fen-phen. Cowley G; Springen K Newsweek; 1997 Sep; 130(13):46-8. PubMed ID: 10173270 [No Abstract] [Full Text] [Related]
47. A collaborative investigation of fenfluramine. Anorexigenic with sedative properties. Elliott BW Curr Ther Res Clin Exp; 1970 Aug; 12(8):502-15. PubMed ID: 4988837 [No Abstract] [Full Text] [Related]
48. Evaluation and treatment of obesity. Azar ST; Zantout MS J Med Liban; 2000; 48(5):310-4. PubMed ID: 12489585 [No Abstract] [Full Text] [Related]
49. [Controled trial of an anorectic (An 448) in the treatment, of childhood obesity]. Canlorbe P; Borniche P; Toublanc JE Nouv Presse Med; 1976 Apr; 5(16):1061-2. PubMed ID: 775433 [No Abstract] [Full Text] [Related]
50. Two new appetite suppressants. Med Lett Drugs Ther; 1974 Jun; 16(13):54. PubMed ID: 4842602 [No Abstract] [Full Text] [Related]
51. [Therapeutic tests of the combination of dimethylphenethylamine and pentobarbital in a slow-release vehicle in the treatment of obese patients]. Castrillo JU; Bialski R Hospital (Rio J); 1970 Jan; 77(1):217-25. PubMed ID: 5309992 [No Abstract] [Full Text] [Related]
52. Phentermine therapy for obesity does not elevate blood pressure. Hendricks EJ; Rothman RB Diabetes Obes Metab; 2011 Oct; 13(10):963-4. PubMed ID: 21896124 [No Abstract] [Full Text] [Related]
54. [Therapeutic effect of various appetite depressants under controlled conditions]. Kreze A; Toman A Bratisl Lek Listy; 1973; 59(4):406-12. PubMed ID: 4751882 [No Abstract] [Full Text] [Related]
55. The long-term management of obesity with continuing pharmacotherapy. Frank A Obes Res; 2004 Nov; 12(11):1821-7. PubMed ID: 15601978 [TBL] [Abstract][Full Text] [Related]
56. Valvular heart disease associated with fenfluramine-phentermine. Marshall EM N Engl J Med; 1997 Dec; 337(24):1775; author reply 1775-6. PubMed ID: 9411252 [No Abstract] [Full Text] [Related]
57. Comparison of continuous and intermittent anorectic therapy in obesity. Munro JF; MacCuish AC; Wilson EM; Duncan LJ Br Med J; 1968 Feb; 1(5588):352-4. PubMed ID: 15508204 [No Abstract] [Full Text] [Related]
58. [Electroencephalographic and statokinesimetric study of perphoxene in man]. Soulairac A Therapeutique; 1971 Apr; 47(4):365-9. PubMed ID: 5564048 [No Abstract] [Full Text] [Related]
59. New medications for weight loss. Murfin M JAAPA; 2012 Dec; 25(12):59-60. PubMed ID: 23600006 [No Abstract] [Full Text] [Related]
60. [Anorexigenic drugs in the treatment of obesity]. Maiz A; Kehr J; Grekin C; Reyes E; Charlín V; Fernández P; Manrique M; Velasco N Rev Med Chil; 1995 May; 123(5):637-40. PubMed ID: 8525212 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]